Research progress on Toll-like receptor agonists and their application in tumor vaccines

doi:10.11958/20253005

Abstract

Abstract:

Toll-like receptor (TLR) agonists, when used as adjuvants in tumor vaccines, can effectively activate the innate immune response and enhance antitumor immune responses. By specifically recognizing pathogen-associated molecular patterns, they activate downstream signaling pathways, promote the maturation and antigen presentation of dendritic cells, and thereby induce strong cellular immunity. Various TLR agonists have shown potential in tumor vaccines to enhance immunogenicity, reverse immune suppression and synergize with immune checkpoint inhibitors. This article reviews the classification, mechanism of action and research progress of TLR agonists in tumor vaccines, aiming to provide a reference for tumor immunotherapy.

Key words: Toll-like receptors, tumor vaccines, agonists, adjuvants, antitumor

CLC Number:

R979.5，R730.5

References 47

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi:10.3322/caac.21834.
[2]	KAWAI T, IKEGAWA M, ORI D, et al. Decoding Toll-like receptors:recent insights and perspectives in innate immunity[J]. Immunity, 2024, 57(4):649-673. doi:10.1016/j.immuni.2024.03.004.
[3]	FARAG N S, BREITINGER U, BREITINGER H G, et al. Viroporins and inflammasomes:a key to understand virus-induced inflammation[J]. Int J Biochem Cell Biol, 2020, 122:105738. doi:10.1016/j.biocel.2020.105738.
[4]	FITZGERALD K A, KAGAN J C. Toll-like receptors and the control of immunity[J]. Cell, 2020, 180(6):1044-1066. doi:10.1016/j.cell.2020.02.041.
[5]	PEREIRA M, GAZZINELLI R T. Regulation of innate immune signaling by IRAK proteins[J]. Front Immunol, 2023, 14:1133354. doi:10.3389/fimmu.2023.1133354.
[6]	CHEN Y H, WU K H, WU H P. Unraveling the complexities of Toll-like receptors:from molecular mechanisms to clinical applications[J]. Int J Mol Sci, 2024, 25(9):5037. doi:10.3390/ijms25095037.
[7]	JIN M, FANG J, WANG J J, et al. Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis:from mechanisms to targeted therapeutics[J]. Acta Pharmacol Sin, 2023, 44(12):2358-2375. doi:10.1038/s41401-023-01123-5.
[8]	ZHAO H, WU L, YAN G, et al. Inflammation and tumor progression:signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021, 6(1):263. doi:10.1038/s41392-021-00658-5.
[9]	MENG T, GAO T, QIAO F, et al. A VZV-gE subunit vaccine decorated with PLA elicits protective cellular immune responses against varicella-zoster virus[J]. Int Immunopharmacol, 2025, 147:114033. doi:10.1016/j.intimp.2025.114033.
[10]	JIANG Y, ZHANG H, WANG J, et al. Exploiting RIG-I-like receptor pathway for cancer immunotherapy[J]. J Hematol Oncol, 2023, 16(1):8. doi:10.1186/s13045-023-01405-9.
[11]	CHAMPION C R. Heplisav-B:A hepatitis B vaccine with a novel adjuvant[J]. Ann Pharmacother, 2021, 55(6):783-791. doi:10.1177/1060028020962050.
[12]	CHAKRABORTY S, YE J, WANG H, et al. Application of toll-like receptors(TLRs)and their agonists in cancer vaccines and immunotherapy[J]. Front Immunol, 2023, 14:1227833. doi:10.3389/fimmu.2023.1227833.
[13]	UMAR M, AFZAL H, MURTAZA A, et al. Lipoprotein signal peptide as adjuvants:leveraging lipobox-driven TLR2 activation in modern vaccine design[J]. Vaccines (Basel), 2025, 13(1):36. doi:10.3390/vaccines13010036.
[14]	XIE D, HAN C, CHEN C, et al. A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation[J]. Bioact Mater, 2024, 37:315-330. doi:10.1016/j.bioactmat.2024.03.035.
[15]	GU Y, YANG J, HE C, et al. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases[J]. Signal Transduct Target Ther, 2023, 8(1):273. doi:10.1038/s41392-023-01479-4.
[16]	KOMAL A, NOREEN M, EL-KOTT A F. TLR3 agonists:RGC100,ARNAX,and poly-IC:a comparative review[J]. Immunol Res, 2021, 69(4):312-322. doi:10.1007/s12026-021-09203-6.
[17]	HSIEH M L, NISHIZAKI D, ADASHEK J J, et al. Toll-like receptor 3:a double-edged sword[J]. Biomark Res, 2025, 13(1):32. doi:10.1186/s40364-025-00739-5.
[18]	WENG M T, YANG S F, LIU S Y, et al. In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models[J]. Pharmacol Res, 2023, 188:106646. doi:10.1016/j.phrs.2023.106646.
[19]	KOERNER J, HORVATH D, HERRMANN V L, et al. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy[J]. Nat Commun, 2021, 12(1):2935. doi:10.1038/s41467-021-23244-3.
[20]	李如月, 向晓辉, 张斌, 等. TLR4信号通路相关miRNAs在炎症反应调节中的研究进展[J]. 天津医药, 2017, 45(7):771-776.
	LI R Y, XIANG X H, ZHANG B, et al. Research progress of TLR4 signaling pathway related miRNAs in inflammatory response[J]. Tianjin Med J, 2017, 45(7):771-776. doi:10.11958/20170207.
[21]	DING D, WEN Y, LIAO C M, et al. Self-adjuvanting protein vaccine conjugated with a novel synthetic TLR4 agonist on virus-like liposome induces potent immunity against SARS-CoV-2[J]. J Med Chem, 2023, 66(2):1467-1483. doi:10.1021/acs.jmedchem.2c01642.
[22]	SEO B, LIM M Y. Balancing harm and harmony:evolutionary dynamics between gut microbiota-derived flagellin and TLR5-mediated host immunity and metabolism[J]. Virulence, 2025, 16(1):2512035. doi:10.1080/21505594.2025.2512035.
[23]	TALUKDER A, RAHMAN M M, RAHI M S, et al. Flagellins as vaccine adjuvants and cancer immunotherapy:recent advances and future prospects[J]. Immunology, 2025, 176(3):277-303. doi:10.1111/imm.70001.
[24]	EULIANO E M, POGOSTIN B H, AGRAWAL A, et al. A TLR7 agonist conjugated to a nanofibrous peptide hydrogel as a potent vaccine adjuvant[J]. Adv Healthc Mater, 2026, 14(3):e2402958. doi:10.1002/adhm.202402958.
[25]	SUN H, LI Y, ZHANG P, et al. Targeting toll-like receptor 7/8 for immunotherapy:recent advances and prospectives[J]. Biomark Res, 2022, 10(1):89. doi:10.1186/s40364-022-00436-7.
[26]	LUO L, WANG X, LIAO Y P, et al. Nanocarrier co-formulation for delivery of a TLR7 agonist plus an immunogenic cell death stimulus triggers effective pancreatic cancer chemo-immunotherapy[J]. ACS Nano, 2022, 16(8):13168-13182. doi:10.1021/acsnano.2c06300.
[27]	GANE E J, DUNBAR P R, BROOKS A E, et al. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression[J]. J Hepatol, 2023, 78(3):513-523. doi:10.1016/j.jhep.2022.09.027.
[28]	KAUR A, BALDWIN J, BRAR D, et al. Toll-like receptor(TLR)agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics[J]. Curr Opin Chem Biol, 2022, 70:102172. doi:10.1016/j.cbpa.2022.102172.
[29]	XU R, WU M, LIU S, et al. Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4+ Treg cells in ovarian cancer cells microenvironment[J]. Cell Death Dis, 2021, 12(1):22. doi:10.1038/s41419-020-03272-5.
[30]	王丹妮, 郑贵杰, 张翼, 等. Toll样受体激动剂及其作为寄生虫疫苗佐剂研究进展[J]. 中国人兽共患病学报, 2024, 40(11):1063-1072.
	WANG D N, ZHENG G J, ZHANG J, et al. Research progress in Toll-like receptor agonist types and applications as adjuvants for parasitics vaccine[J]. Chinese Journal of Zoonoses, 2024, 40(11):1063-1072. doi:10.3969/j.issn.1002-2694.2024.00.158.
[31]	CHENG Y, BORCHERDING N, OGUNSAKIN A, et al. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent[J]. Sci Rep, 2021, 11(1):1535. doi:10.1038/s41598-020-80957-z.
[32]	MACKMAN R L, MISH M, CHIN G, et al. Discovery of GS-9688 (selgantolimod) as a potent and selective oral Toll-like receptor 8 agonist for the treatment of chronic hepatitis B[J]. J Med Chem, 2020, 63(18):10188-10203. doi:10.1021/acs.jmedchem.0c00100.
[33]	FEHRI E, ENNAIFER E, BEL HAJ RHOUMA R, et al. TLR9 and glioma:friends or foes?[J]. Cells, 2022, 12(1):152. doi:10.3390/cells12010152.
[34]	KOU M, WANG L. Surface toll-like receptor 9 on immune cells and its immunomodulatory effect[J]. Front Immunol, 2023, 14:1259989. doi:10.3389/fimmu.2023.1259989.
[35]	XING J, ZHAO X, LI X, et al. The recent advances in vaccine adjuvants[J]. Front Immunol, 2025, 16:1557415. doi:10.3389/fimmu.2025.1557415.
[36]	LIU M, LIU L, SONG Y, et al. Targeting macrophages:a novel treatment strategy in solid tumors[J]. J Transl Med, 2022, 20(1):586. doi:10.1186/s12967-022-03813-w.
[37]	GUNST J D, HØJEN J F, PAHUS M H, et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence:the randomized phase 2a TITAN trial[J]. Nat Med, 2023, 29(10):2547-2558. doi:10.1038/s41591-023-02547-6.
[38]	LEMKE-MILTNER C D, BLACKWELL S E, YIN C, et al. Antibody opsonization of a TLR9 agonist-containing virus-like particle enhances in situ immunization[J]. J Immunol, 2020, 204(5):1386-1394. doi:10.4049/jimmunol.1900742.
[39]	SULTAN H, SALAZAR A M, CELIS E. Poly-ICLC,a multi-functional immune modulator for treating cancer[J]. Semin Immunol, 2020, 49:101414. doi:10.1016/j.smim.2020.101414.
[40]	HUANG L, RONG Y, TANG X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer[J]. Mol Cancer, 2022, 21(1):45. doi:10.1186/s12943-022-01515-x.
[41]	LI R, HAO Y, PAN W, et al. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy[J]. Acta Biomater, 2023, 171:482-494. doi:10.1016/j.actbio.2023.09.013.
[42]	ZHANG L, WU S, QIN Y, et al. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy[J]. Nano Lett, 2019, 19(7):4237-4249. doi:10.1021/acs.nanolett.9b00030.
[43]	BALJON J J, KWIATKOWSKI A J, PAGENDARM H M, et al. A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists[J]. ACS Nano, 2024, 18(9):6845-6862. doi:10.1021/acsnano.3c04471.
[44]	LEŚNIAK M, LIPNIARSKA J, MAJKA P, et al. The role of TRL7/8 agonists in cancer therapy,with special emphasis on hematologic malignancies[J]. Vaccines (Basel), 2023, 11(2):277. doi:10.3390/vaccines11020277.
[45]	陈敏纯, 薛润青, 赵新, 等. 肿瘤疫苗TCL/CpG@GNP的构建及评价[J]. 天津医药, 2025, 53(10):1021-1026.
	CHEN M C, XUE R Q, ZHAO X, et al. Development and evaluation of the tumor vaccine TCL/CpG@GNP[J]. Tianjin Med J, 2025, 53(10):1021-1026. doi:10.11958/20251525.
[46]	LI F, DING X, LV Z, et al. A DNA-polymer hybrid nanocomplex based bi-adjuvant vaccine for tumor immunotherapy[J]. Nano Today, 2024, 54:102061. doi:10.1016/j.nantod.2023.102061.
[47]	NI Q, ZHANG F, LIU Y, et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer[J]. Sci Adv, 2020, 6(12):eaaw6071. doi:10.1126/sciadv.aaw6071.